HH
KIN

Hilltop Holdings’s Kindred Biosciences, Inc. KIN Stock Holding History

Hilltop Holdings’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,000
Closed -$86K – 336
2017
Q2 		$86K Buy
+10,000
New +$71.7K 0.03% 309

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Hilltop Holdings's KIN Position: Q3 2017 in Review

Hilltop Holdings sold out of Kindred Biosciences, Inc. (KIN) in Q3 2017, closing a stake of 10,000 shares — an estimated $86K sold.

Hilltop Holdings first reported a position in KIN in Q2 2017 and held it in 1 quarter. The position peaked at $86K in Q2 2017. 67 funds tracked by Wall St. Rank hold KIN as of Q3 2017.

  • Hilltop Holdings reported no remaining Kindred Biosciences, Inc. position as of Q3 2017 after selling out during the quarter.
  • Hilltop Holdings sold 10,000 Kindred Biosciences, Inc. shares in Q3 2017, an estimated $86K.
  • Hilltop Holdings first reported a position in Kindred Biosciences, Inc. in Q2 2017 and held it in 1 quarter.
  • Hilltop Holdings's Kindred Biosciences, Inc. position peaked at $86K in Q2 2017.
  • 67 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2017.

Based on Hilltop Holdings's 13F filing for Q3 2017, filed 14 Nov 2017.